PITTSBURGH, Nov. 10 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc.
(NYSE: MYL) today announced that the U.S. Food and Drug Administration (FDA)
has granted final approval for Mylan Pharmaceuticals Inc.'s Abbreviated New
Drug Applications (ANDAs) for Oxybutynin Chloride Extended-release Tablets, 5
mg and 10 mg, and Mylan has launched these products immediately. Oxybutynin
Chloride ER Tablets are the generic version of Alza Corporation's Ditropan
XL(R) Extended-release Tablets. Ditropan XL(R) had U.S. sales of approximately
$380 million during the 12-month period ended June 30, 2006, with more than
82% of the volume in the 5 mg and 10 mg strengths, according to IMS.
    Robert J. Coury, Mylan's Vice Chairman and Chief Executive Officer
commented: "This is the latest milestone achievement in Mylan's long history
of successfully developing difficult to formulate and difficult to manufacture
generic products. Mylan has once again differentiated itself in the industry
through the successful development of this product, and based on the limited
number of competitors that have filed oxybutynin applications, we expect that
it will be a valuable component of our product portfolio for the 180 days of
market exclusivity and beyond."
    Mylan is the first generic drug company to file ANDAs with the FDA for 5
mg and 10 mg Ditropan XL(R), and as such, the company has 180 days of market
exclusivity for those strengths. Mylan has entered into two agreements with
Ortho-McNeil Pharmaceuticals and Alza that ensures Mylan's ability to launch
the 15 mg strength at market formation.
    Mylan Laboratories Inc. is a leading pharmaceutical company with three
principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc.
and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets and
distributes an extensive line of generic and proprietary products.
    For more information about Mylan, please visit http://www.mylan.com.
    This press release includes statements that constitute "forward-looking
statements," including with regard to the product's expected role in the
Company's portfolio and anticipated market exclusivity.  These statements are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.  Because such statements inherently involve
risks and uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements.  Factors that
could cause or contribute to such differences include, but are not limited to:
the possible negative effects of any interruption of manufacture of the
products; uncertainties regarding market acceptance and demand for the
products; dependence on third-party suppliers and distributors for raw
materials; risks inherent in contracts, including the breach or
unenforceability of any key provision; and the other risks detailed in the
Company's periodic filings with the Securities and Exchange Commission. The
Company undertakes no obligation to update these statements for revisions or
changes after the date of this release.

SOURCE  Mylan Laboratories Inc.


    CONTACT:  Patrick Fitzgerald of Mylan Laboratories Inc., +1-724-514-1800

    Web site:  http://www.mylan.com